{
    "nct_id": "NCT05320588",
    "official_title": "A Phase 1/2 Study of BIO-106 As Monotherapy or In Combination With Pembrolizumab in Patients With Advanced Cancers (StarBridge-1)",
    "inclusion_criteria": "* Patients histologically or cytologically documented, locally advanced or metastatic solid tumor.\n* Disease progression confirmed by imaging or other objective evidence after having received standard treatment; or patients with refractory solid tumors who cannot tolerate standard treatment or have contraindications to standard treatment.\n* Measurable disease as determined by RECIST v.1.1 or bone only disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of severe hypersensitivity to any ingredient of the study drug(s), including pembrolizumab or other monoclonal antibody.\n\nImpaired cardiac function or history of clinically significant cardiac disease\n\n* Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.\n* Active SARS-CoV-2 infection.\n* Untreated central nervous system (CNS), epidural tumor or metastasis, or brain metastasis.\n\nOther protocol defined inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}